335 related articles for article (PubMed ID: 37511937)
21. Long term results of down-staging and liver transplantation for patients with hepatocellular carcinoma beyond the conventional criteria.
Ravaioli M; Odaldi F; Cucchetti A; Trevisani F; Piscaglia F; De Pace V; Bertuzzo VR; Neri F; Golfieri R; Cappelli A; D'Errico A; Cescon M; Del Gaudio M; Fallani G; Siniscalchi A; Morelli MC; Ciccarese F; Di Marco M; Farinati F; Giannini EG; Pinna AD
Sci Rep; 2019 Mar; 9(1):3781. PubMed ID: 30846792
[TBL] [Abstract][Full Text] [Related]
22. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.
Pompili M; Francica G; Ponziani FR; Iezzi R; Avolio AW
World J Gastroenterol; 2013 Nov; 19(43):7515-30. PubMed ID: 24282343
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
24. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series.
Chen Z; Hong X; Wang T; Guo Y; Huang C; Li M; He X; Ju W; Chen M
Ann Palliat Med; 2021 Sep; 10(9):9354-9361. PubMed ID: 34412496
[TBL] [Abstract][Full Text] [Related]
25. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
26. Conversion therapy in liver transplantation for hepatocellular carcinoma: What's new in the era of molecular and immune therapy?
Jiang C; Sun XD; Qiu W; Chen YG; Sun DW; Lv GY
Hepatobiliary Pancreat Dis Int; 2023 Feb; 22(1):7-13. PubMed ID: 36825482
[TBL] [Abstract][Full Text] [Related]
27. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Machairas N; Tsilimigras DI; Pawlik TM
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454923
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review.
Muhammad H; Tehreem A; Ting PS; Gurakar M; Li SY; Simsek C; Alqahtani SA; Kim AK; Kohli R; Gurakar A
J Clin Transl Hepatol; 2021 Oct; 9(5):738-748. PubMed ID: 34722189
[TBL] [Abstract][Full Text] [Related]
29. Outcomes associated with the intention of loco-regional therapy prior to living donor liver transplantation for hepatocellular carcinoma.
Wu TH; Wang YC; Cheng CH; Lee CF; Wu TJ; Chou HS; Chan KM; Lee WC
World J Gastrointest Surg; 2020 Jan; 12(1):17-27. PubMed ID: 31984121
[TBL] [Abstract][Full Text] [Related]
30. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
Li Q; Han J; Yang Y; Chen Y
Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.
Alghamdi S; Al-Hamoudi W
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958291
[TBL] [Abstract][Full Text] [Related]
32. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?
Piñero F; Thompson M; Marín JI; Silva M
World J Transplant; 2020 Nov; 10(11):297-306. PubMed ID: 33312891
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
[TBL] [Abstract][Full Text] [Related]
34. Examinations of Factors Influencing Survival of Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience From Budapest.
Piros L; Fehérvári I; Görög D; Nemes B; Szabó J; Gerlei Z; Végső G; Kóbori L; Máthé Z
Transplant Proc; 2015 Sep; 47(7):2201-6. PubMed ID: 26361680
[TBL] [Abstract][Full Text] [Related]
35. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation.
Schmitz S; Lurje G; Ulmer F; Andert A; Bruners P; Schulze-Hagen M; Neumann U; Schoening W
Hepatobiliary Pancreat Dis Int; 2019 Jun; 18(3):228-236. PubMed ID: 30718181
[TBL] [Abstract][Full Text] [Related]
36. 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon's perspective.
Cheung TT; Ho CL; Lo CM; Chen S; Chan SC; Chok KS; Fung JY; Yan Chan AC; Sharr W; Yau T; Poon RT; Fan ST
J Nucl Med; 2013 Feb; 54(2):192-200. PubMed ID: 23321459
[TBL] [Abstract][Full Text] [Related]
37. Preoperative Immunotherapy in Hepatocellular Carcinoma: Current State of the Art.
Laschtowitz A; Roderburg C; Tacke F; Mohr R
J Hepatocell Carcinoma; 2023; 10():181-191. PubMed ID: 36789252
[TBL] [Abstract][Full Text] [Related]
38. Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Choi JY
Oncology; 2011; 81 Suppl 1():141-7. PubMed ID: 22212948
[TBL] [Abstract][Full Text] [Related]
39. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation.
Hanje AJ; Yao FY
Curr Opin Organ Transplant; 2008 Jun; 13(3):234-40. PubMed ID: 18685309
[TBL] [Abstract][Full Text] [Related]
40. Combination immunotherapy for hepatocellular carcinoma.
Rimassa L; Finn RS; Sangro B
J Hepatol; 2023 Aug; 79(2):506-515. PubMed ID: 36933770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
